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assessment would have significant resource and financial
implications, given the relative limited capacity of these
modalities compared to ultrasound in most societies.
Neither modality is without risk. CT involves significant
radiation doses and both CT and MRI require the
administration of intravenous contrast for optimum
examination which can be associated with significant
side effects.7
Despite its limitations, ultrasound will remain the pri-
mary imaging modality for HCC for the foreseeable
future. It is therefore crucial to maximise the perfor-
mance of ultrasound as a screening tool by ensuring it is
performed and reported by adequately trained operators;
they need to be experienced in hepatobiliary imaging in
order to obtain high-quality diagnostic examinations and
to minimise the referral rate for CT/MRI imaging
surveillance, and the ensuing financial and resource
implications associated with this.
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The letter from Dr Patel1 raises some interesting points
that are worthy of further discussion.
Surveillance ultrasound has the potential for high
sensitivity and specificity as demonstrated in prospective
cohort studies,2 although recent data have demonstrated
a substantial gap between its efficacy and its effective-
ness when implemented in clinical practice, including
low sensitivity for early tumour detection3 and subopti-
mal specificity leading to screening-related harms.4 Our
study adds to this literature suggesting subgroups of
patients, including obese individuals, patients with non-
alcoholic steatohepatitis (NASH), and those with Child
Pugh B or C cirrhosis, may be particularly prone to
suboptimal ultrasound quality and the potential for
surveillance failure in detecting early stage hepatocellu-
lar carcinom.5
Dr Patel highlights that ultrasounds in our study
were interpreted retrospectively based on stored hard
copy images, resulting in an overestimation of the pro-
portion of inadequate exams. Although we agree real-
time performance of the exam by the interpreting radi-
ologist may improve exam quality, this is unfortunately
not standard practice in many parts of the world,
including the USA. Instead, technologists typically per-
form ultrasounds using a set protocol, recording repre-
sentative still images to document exam completeness,
which are subsequently interpreted by radiologists at a
later time. It is possible operator experience, specific
technologist training, and real-time exam interpretation
could overcome some of ultrasound’s operator depen-
dency and improve its performance for early HCC
detection; however, these interventions are unlikely to
overcome all of ultrasound’s potential limitations, and
some exams will still likely be compromised by poor
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visualisation in obese patients and those with nodular,
heterogeneous hepatic parenchyma.5
Although alternative surveillance strategies may be
needed long term as HCC epidemiology shifts from hep-
atitis C to NASH-related cirrhosis, we agree with Dr
Patel that using multi-phasic CT and MRI in all patients
with cirrhosis is likely not feasible given issues of cost,
potential harms, and radiologic capacity. Furthermore,
the performance of CT and MRI for surveillance in
patients prone to ultrasound failure, such as those with
obesity, is unknown. Discovery of highly sensitive and
specific serum biomarkers is an important effort in
improving HCC surveillance performance, as some bio-
marker panels have shown potentially high sensitivity for
early HCC detection.6 However, we are still likely years
away from sufficient validation for their routine use in
clinical practice. In the interim, ultrasound, with or with-
out alpha fetoprotein, continues to be our primary HCC
surveillance modality and efforts to maximise ultrasound
effectiveness are critical.
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Symptom-based diagnostic criteria are the current pre-
ferred method for diagnosing irritable bowel syndrome
(IBS). However, these have been shown to perform only
modestly in several studies.1–3 As a result, interest in the
use of biomarkers to facilitate an accurate diagnosis of IBS
has increased although, in a recent meta-analysis, they
performed no better than symptom-based diagnostic crite-
ria, or were not available outside of a research setting.4
Aggio et al.5 have conducted a study that uses a pro-
totype device based on gas chromatography to separate
volatile organic compounds (products from digestion
and fermentation by the intestinal microbiota), from fae-
cal gas, in order to identify patterns that could be used
to differentiate between IBS, inflammatory bowel disease
and health. Patients were recruited prospectively between
October 2010 and October 2011, and faecal samples were
obtained from 28 patients with IBS, as defined by the
Rome II criteria [26 patients with diarrhoea-predominant
IBS (IBS-D)], 33 patients with active inflammatory bowel
disease, 50 patients with inactive inflammatory bowel
disease and 41 healthy controls. A simple clinical activity
index score ≥ 3 or a Harvey Bradshaw index ≥ 4 were
used to define active ulcerative colitis and active Crohn’s
disease respectively.
Faecal samples were stored at 20 °C, and samples
were analysed by gas chromatography, which works by
characterising the volatile organic compounds contained
in the faecal samples. Patterns in the volatile compounds
were then detected for each of the individual medical dis-
orders. This prototype device had a runtime of only
40 min, therefore potentially providing a means for a
point-of-care test. The device was able to distinguish
between IBS and active inflammatory bowel disease with
a maximum sensitivity and specificity of 93% and 90%,
respectively; between IBS and inactive inflammatory
bowel disease with a maximum sensitivity and specificity
of 89% and 80%, respectively; between IBS and all
inflammatory bowel disease patients with a maximum
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